Cannabinoids as an ingredient for use in pharmaceuticals, F&B and other industries is steadily gaining in interest across the globe, While R&D and technology developments are on the rise, the industry is still emerging considering the regulatory scenario and the technology limitations.With many technology developers focusing on overcoming challenges and product developmental efforts, new business models need to play with all possible interactions among stakeholders in order to create a smooth environment for commercialization.
In countries such as USA, advancing regulations is encouraging the innovation ecosystem to flourish and new commercialization opportunities are expected to rise in the coming 3-5 years.Competition models are gaining increasing attention in order to face challenges and capture value.
Technology and business synergies are required to optimal route for commercialization with industry convergence needed to diversify the business opportunities across industries.
Our reports have been used by over 10K customers, including:
“ASN002 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Hand Eczema in 7 Major Markets. A detailed picture of the ASN002 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period...
“Postoperative pain - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...
“MT-102 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Cancer Cachexia in 7 Major Markets. A detailed picture of the MT-102 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period...
“TTHX 1114 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Fuchs Endothelial Dystrophy in 7 Major Markets. A detailed picture of the TTHX 1114 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for...
“UBLITUXIMAB + UMBRALISIB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diffuse Large B-Cell Lymphoma in 7 Major Markets. A detailed picture of the UBLITUXIMAB + UMBRALISIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the...